Trial Profile
Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Carboplatin
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 21 Sep 2020 Planned primary completion date changed from 1 Aug 2018 to 2 Aug 2016.
- 21 Sep 2020 Planned End Date changed to 3 Aug 2016.
- 21 Sep 2020 Status changed from recruiting to withdrawn prior to enrolment (FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol we only drafted it to get the IND open - never initiated)